Océane Pointeau
YOU?
Author Swipe
View article: Blockade of cannabinoid CB<sub>1</sub> receptors potentiates the anti‐fibrotic effects mediated by SGLT2 inhibition in a mouse model of diabetic nephropathy
Blockade of cannabinoid CB<sub>1</sub> receptors potentiates the anti‐fibrotic effects mediated by SGLT2 inhibition in a mouse model of diabetic nephropathy Open
Background and purpose Diabetic nephropathy (DN) is a common complication of diabetes. Current treatments include renin‐angiotensin‐aldosterone system (RAAS) blockers and sodium‐glucose co‐transporter 2 (SGLT2) inhibitors. The cannabinoid …
View article: HSP110 Regulates the Assembly of the SWI/SNF Complex
HSP110 Regulates the Assembly of the SWI/SNF Complex Open
HSP110 is a ubiquitous chaperone contributing to proteostasis. It has a disaggregation activity and can refold denatured proteins. It can regulate fundamental signaling pathways involved in oncogenesis, such as Wnt/β-catenin, NF-κB and STA…
View article: A Simplified and Robust Model for the Study of Diabetic Nephropathy: Streptozotocin-Induced Diabetic Mice Fed a High-Protein Diet
A Simplified and Robust Model for the Study of Diabetic Nephropathy: Streptozotocin-Induced Diabetic Mice Fed a High-Protein Diet Open
To better understand diabetic nephropathy (DN), developing accurate animal models is crucial. Current models often fail to fully mimic human DN, showing only mild albuminuria, glomerular hypertrophy, and limited mesangial matrix expansion.…
View article: Therapeutic potential of a novel peripherally restricted CB1R inverse agonist on the progression of diabetic nephropathy
Therapeutic potential of a novel peripherally restricted CB1R inverse agonist on the progression of diabetic nephropathy Open
Objective This study assessed the efficacy of INV-202, a novel peripherally restricted cannabinoid type-1 receptor (CB1R) inverse agonist, in a streptozotocin-induced type-1 diabetes nephropathy mouse model. Methods Diabetes was induced in…